Seer Inc. Q2 2026 Earnings: Revenue Misses $3.1 Million
Seer Inc. (Nasdaq: SEER) reported Q2 2026 revenue of $3.1 million, below consensus of $4.0 million, and a net loss of $0.31 per share versus a $0.22 loss expected. The company reaffirmed full-year 2026 revenue guidance of $16 million to $18 million. Shares fell about 2.78% after hours to $2.10.
How this was made
The 30-second read
Why it matters
The key tradable signal is the Q2 revenue miss versus consensus and the immediate after-hours decline, partially offset by lower operating expenses and reaffirmed FY revenue guidance.
Market read
Traders likely reprice near-term growth expectations after the Q2 revenue shortfall, while monitoring whether cost cuts translate into accelerating revenue in subsequent quarters.
What to watch
Large cash balance ($209.5M) and gross margin near 49% could reduce balance-sheet risk, potentially cushioning further downside if revenue stabilizes.
Background
Seer is a proteomics technology company selling research-use-only Proteograph instruments, consumables, and software.
Ticker impact
Seer reported Q2 2026 revenue of $3.1M, below $4.0M consensus, and shares fell 2.78% after hours despite reaffirmed full-year guidance.
Bearish bias for the next few sessions as investors weigh the revenue shortfall versus guidance reaffirmation.
The article provides a concrete earnings miss (revenue and EPS vs consensus) plus the immediate after-hours reaction, while noting operating expense reductions and unchanged FY revenue range.
Market effects
Reinforces that early-stage proteomics tools companies can see valuation pressure when revenue growth lags, even with cost discipline.
Limited, company-specific move for a small-cap Nasdaq name.
Low, no cross-border deal, regulation, or supply-chain shock described.
Counterpoint
Cost reductions and reaffirmed FY guidance may indicate the miss is temporary, with operating leverage improving into later quarters.
Key entities
- companySeer Inc.
Proteomics technology company reporting Q2 2026 results and reaffirming FY 2026 revenue guidance.
- executiveOmid Farokhzad
CEO who highlighted customer presentations on AI-driven proteomics at ASMS.
- executiveDavid Horn
CFO who reaffirmed FY 2026 revenue guidance of $16M to $18M.
